#$%^&*AU2018226488A120180927.pdf#####ABSTRACT A method of treating a drug resistant ovarian cancer, breast cancer, lung cancer, non-small cell lung cancer, glioblastoma, melanoma, bladder cancer, head and neck cancer, renal cell cancer, colorectal cancer, lymphoma, leukemia, multiple myeloma, or hepatocellular carcinoma, includes administering an effective amount of LXRP agonist, wherein the LXRs agonist is compound 2 or compound 25, or a pharmaceutically acceptable salt thereon, the compound 2 and compound 25 being CF3 CF 3 C1 C1 N N CH3 0 N OH . 0 OH 2 25